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Summary
Although preclinical and clinical studies have demonstrated that relaxin (RLX) amelio-
rates impaired renal function by exerting antifibrotic and regenerative effects, its role in renal 
ischemia/reperfusion (I/R) injury has never been investigated. Using a well-known rat model 
of 1h bilateral renal artery occlusion followed by 6 h reperfusion, we investigated the effects 
of human recombinant RLX (5 µg /Kg e.v.) given both at the beginning and after 3 h reperfu-
sion. Serum and urinary indicators of renal injury and dysfunction were measured. Interesting-
ly, administration of the exogenous RLX attenuated all markers of renal injury and dysfunction 
caused by I/R. Overall, we document here, for the first time, that RLX protects against I/R-in-
duced renal injury and dysfunction. The results of this study offer good perspectives for the 
clinical potential of RLX in the medical treatment of renal diseases.
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Although initially perceived as being merely a peptide hormone of ovarian ori-
gin involved in the periparturient widening of the pubic symphysis, relaxin (RLX) 
has been later shown to exert a broad range of biological effects on many organs 
and apparatus, including the cardiovascular system (Bani et al., 2011). We and oth-
ers have shown that RLX affords a clear-cut protection against ischemia/reperfu-
sion (I/R) injury in the heart, brain, intestine and lung (Bani et al., 1998; Masini et 
al., 2006; Alexiou et al., 2010). Both RLX and its main receptor, named relaxin fami-
ly peptide receptor 1 (RXFP1), are expressed in both the human and rodent kidney 
and growing evidence demonstrates that RLX exerts relevant antifibrotic and regen-
erative effects in several experimental models of renal fibrosis (Samuel et al., Curr 
Opin 2009). However, to the best of our knowledge, there is no information on the 
role of RLX in renal I/R injury, which is one of the most common patophysiological 
event leading to acute kidney injury (AKI), a life-threatening condition associated 
with high morbidity and mortality. Thus, we have investigated the effects of RLX 
administration on the recovery of renal function following I/R injury. Anesthetized 
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male Wistar rats rats were subjected to bilateral renal occlusion for 1h using non-
traumatic artery clamps to clamp the renal pedicles, followed by reperfusion for 6h. 
Sham-operated rats underwent surgical procedures identical to those used for I/R 
except that artery clamps were not applied. At the end of the reperfusion, the anes-
thetized rats were killed by aortic exsanguinations and the kidneys were isolated, 
weighed, and rapidly freeze-clamped and stored at −80 °C. Animal care was in com-
pliance with Italian regulations on the protection of animals used for experimental 
and other scientific purposes (D.M. 116/92). The experimental protocol, approved by 
the Turin University Ethics Committee, was performed as described elsewhere (Col-
lino et al., 2011). A group of rats received human recombinant RLX (5 µg /Kg e.v.) 
both at the beginning and after 3 h reperfusion. When compared to sham-operated 
rats, rats that underwent I/R exhibited a significant increase in serum creatinine and 
urea and attenuation in creatinine clearance (CCL) and urine flow, thus indicating 
renal dysfunction and reperfusion injury (Table 1). Tubular injury is suggested by 
a significant increase in urinary excretion of N-Acetyl-β-glucosaminidase (NAG), a 
well-known marker of tubular cell dysfunction. Compared to rats subjected to I/R 
only, therapeutic administration of RLX during reperfusion significantly attenuated 
both glomerular and tubular dysfunction caused by renal I/R, as shown by statisti-
cally significant modification in levels of serum creatinine, serum urea, CCL, urine 
flow and urinary NAG excretion (Table 1). Overall, the results of this study are the 
first to directly demonstrate the beneficial effects of acute RLX administration during 
renal I/R injury, thus suggesting a new potential therapeutic approach for the treat-
ment of AKI.








Serum Urea, mg/dL 13.32±1.84* 44.32±6.18 23.58±3.64*
Serum Creatinine, mg/dL 1.12±0.07* 2.55±0.26 1.75±0.11*
Creatinine Clearance, mL/min 0.056±0.004* 0.007±0.004 0.021±0.002*
Urinary flow, mL/min/100 g bw 0.0076±0.001* 0.0044±0.0008 0.0091±0.0007*
Urinary NAG, IU/L 20.20±2.44* 56.34±7.87 28.87±4.21*
Data are means±S.D. * p< 0.01 vs I/R
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